ENSYSCE BIOSCIENCES, INC. Debt Instrument, Face Amount
ENSYSCE BIOSCIENCES, INC. (ENSC) had Debt Instrument, Face Amount of $196.84 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentFaceAmount · last filed 2026-08-13
- 2026-06-30: Debt Instrument, Face Amount $196.84K.
- 2026-03-31: Debt Instrument, Face Amount $216.00K.
- 2025-12-31: Debt Instrument, Face Amount $279.95K.
- 2025-09-30: Debt Instrument, Face Amount $364.07K.
| Period end | Debt Instrument, Face Amount |
|---|---|
| 2026-06-30 | $196.84K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $216.00K 10-Q · filed 2026-05-15 |
| 2025-12-31 | $279.95K 10-Q · filed 2026-08-13 |
| 2025-09-30 | $364.07K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $404.05K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $240.07K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $287.29K 10-K · filed 2026-03-30 |
| 2024-09-30 | $380.87K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $448.15K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $266.93K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $2.03M 10-K · filed 2025-03-10 |
| 2022-12-31 | $4.10M 10-K · filed 2024-03-15 |
| 2022-09-30 | $8.86M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $2.65M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $7.63M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $14.03M 10-K · filed 2023-03-30 |
| 2021-09-30 | $5.98M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $450.00K 10-Q · filed 2021-08-16 |
| 2020-12-31 | $4.40M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |